| Date: |
December 18, 2002 |
Back |
| Contact: |
David Rowe, Vice President, New Business Development, 317-580-8288, drowe@parapro.com |
|
Carmel, IN. - David Rowe has joined ParaPRO Pharmaceuticals as Vice President, New Business Development. He will lead efforts to develop and commercialize Spinosad technology for the control of human lice. These rights were recently acquired from the Elanco division of Eli Lilly and Company.
David worked for Eli Lilly and Company for 10 years, before moving to the DowElanco joint venture between Lilly and Dow Chemical. For Dow, he served as Global Director of Strategic Development, and Global Business Unit Leader for Biotechnology. His responsibilities at Dow included technology acquisition and development in fields including therapeutics and vaccines. Most recently, David served as Managing Director of Synapse Life Sciences Ventures.
David’s educational background includes a Bachelors degree from Harvard College and a Masters of Business Administration from the Harvard Graduate School of Business.
ParaPRO is an affiliate of SePRO Corporation, of Carmel, Indiana. SePRO Corporation, founded in 1994, has built its business by bringing innovative solutions to complex environmental problems throughout the world.
ParaPRO LLC was founded in 2002 when SePRO Corporation of Carmel, IN purchased the worldwide rights to develop and market Spinosad for the control of lice in human health from Eli Lilly and Company. The compound is currently in clinical trials at multiple sites across the United States. More information on ParaPRO can be found at www.parapro.com.
SePRO Corporation is recognized as an industry leader in providing the highest level of technical service to customers who operate in specialty markets of the USA. To learn more about SePRO Corporation, its products, services and technologies, call 1-800-419-7779 or visit the SePRO web site at www.sepro.com.